ArticleClinical and translational radiation oncology2022

NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience.

Alexander F Bagley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.